Abstract
Animal experiments were carried out to investigate whether a protective effect can be achieved in endotoxemia by intravenous (i.v.) application of a polyclonal immunoglobulin preparation (IVIG-IgG/A/M) enriched with 12% IgM and 12% IgA. Following administration of IVIG-IgG/A/M (500 mg/kg), endotoxemia was induced by intraperitoneal inoculation of a sub-lethal dose (5×108 CFU/kg) of Escherichia coli (E. coli) and subsequent i.v. administration of an antimicrobial agent (Imipenem). Plasma endotoxin activity, IL-6 activity, mean arterial pressure, and skeletal muscle oxygen pressure (tpO2) were measured at regular intervals over a total observation period of 7 h. Prophylactic administration of IVIG-IgG/A/M was found to significantly attenuate (P<0.01) the antibiotic-induced increase in endotoxin activity as compared to the albumin control group. Limited endotoxemia in the IgG/A/M group was associated with reduced levels of circulating IL-6 (P<0.01). Both lipopolysaccharide-induced hypotension and depression of tissue oxygenation were attenuated (P<0.01) by pre-treatment with IVIG-IgG/A/M. The experimental results suggest that in endotoxemia the polyclonal immunoglobulin preparation has a prophylactic protective effect on the acute phase responses and reduces the cardiodepressant effects of E. coli septicaemia.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Abel FL (1989) Myocardial function in sepsis and endotoxin shock. Am J Physiol 257:1265–1281
Apri M, Renneberg J, Andersen H-K, Nielsen B, Larsen SO (1995) Bacteremia at a Danish University Hospital during a twenty-five-year period (1968–1992). Scand J Infect Dis 27:245–251
Autenrieth IB, Schwarzkopf A, Ewald JH, Karch H, Lissner R (1995) Bactericidal properties of Campylobacter jejuni-specific IgM antibodies in commercial immunoglobulin preparations. Antimicrob Agents Chemother 39(9):1965–1969
Ayala A, Kisala JM, Felt JA, Perrin MM, Chaudry IH (1992) Does endotoxin tolerance prevent the release of inflammatory monokines (interleukin-1, interleukin-6, or tumor necrosis factor) during sepsis? Arch Surg 127:191–197
Baumgartner JD, Glauser MP (1993) Immunotherapy of endotoxemia septicemia. Immunobiology 187:464–477
Baumgartner JD, Glauser MP, McCutchan JA, Ziegler EJ, Melle G van, Klauber MR, Vogt M, Muehlen E, Luethy R, Chiolero R, Geroulanos S (1985) Prevention of gram-negative shock and death in surgical patients by antibody to endotoxin core glycolipid. Lancet 2:59–63
Beerthuizen RI, Goris JA, Kreuzer FJ (1989) Early detection of shock in critically ill patients by skeletal muscle PO2 assessment. Arch Surg 124:853–855
Bone RC (1991) A critical evaluation of new agents for the treatment of sepsis. JAMA 266:1686–1690
Brandtzaeg IP, Kierulf P, Gaustad P, Skulberg A, Bruun JN, Halvorsen S, Sørensen E (1988) Plasma endotoxin as a predictor of multiple organ failure and death in systemic meningococcal disease. J Infect Dis 159:195–204
Burd RS, Battafarano RJ, Cody CS, Farber MS, Ratz CA, Dunn DL (1993) Anti-endotoxin monoclonal antibodies inhibit secretion of tumor necrosis factor-alpha by two distinct mechanisms. Ann Surg 218:250–261
Calandra T, Glauser MP, Schellekens J, Verhoef J, et al (1988) Treatment of gram-negative septic shock with human IgG antibody to Escherichia coli J5: a prospective, double-blind, randomized trail. Infect Dis 158:312–319
Caplan ES (1993) Role of immunmodulator therapy in sepsis. Am J Surg 165[Suppl 2A]: 20–24
Cross AS, Opal SM (1995) Endotoxin’s role in Gram-negative bacterial infection. Curr Opin Infect Dis 8:156–163
Damas P, Ledoux D, Nys M, Vrindts Y, DeGroote D, Franchimont P, Lamy M (1992) Cytokine serum level during severe sepsis in human IL-6 as a marker of severity. Ann Surg 215:356–362
Danner RL, Elin RJ, Hosseini JM, Wesley RA, Reilly JM, Parrillo JE (1991) Endotoxemia in human septic shock. Chest 99:169–175
De Maria A (1988) Immunization with rough mutants Salmonella minnesota: initial studies in human subjects. J Infect Dis 158:301–311
De Simone C, Delogu G, Corbetta G (1988) Intravenous immunoglobulins in association with antibiotics: a therapeutical trial in septic intensive care unit patients. Crit Care Med 16:23–26
Dofferhoff AS, Nijland JH, Vries-Hospers HG de, Mulder PO, Weits J, Bom VJ (1991) Effects of different types of antimicrobial agents on endotoxin release from gram-negative bacteria: an in-vitro and in-vivo study. Scand J Infect Dis 23:745–754
Dominioni L, Dionigi R, Zanello M, Chiaranda M, Dionigi R, Acquarolo A, Ballabio A, Sguotti C (1991) Effects of high-dose IgG on survival of surgical patients wth sepsis scores of 20 or greater. Arch Surg 126:236–240
Fiddian-Green RG (1991) Should measurements of tissue pH and PO2 be included in the routine monitoring of intensive care unit patients? Crit Care Med 19:141–143
Flemming I, Julou-Schaeffer G, Gray GA, Parratt JR, Stoclet JC (1991) Evidence that an L-arginine/nitric oxide dependent elevation of tissue cyclic GMP content is involved in depression of vacular reactivity by endotoxin. Br J Pharmacol 103:1047–1052
Garbett ND, Munro CS, Cole PJ (1989) Opsonic activity of a new intravenous immunoglobulin preparation: Pentaglobin compared with Sandoglobin. Clin Exp Immunol 76:8–12
Gillis S, Ferm FF, Ou W, Smith KA (1978) T cell growth factor: parameters of production and a quantitative microassay for activity. J Immunol 120:2027–2032
Greenberg RN, Wilson KM, Kunz AY, Wedel NI, Gorelick KJ (1992) Observations using antiendotoxin antibody (E5) as adjuvant therapy in humans with suspected, serious, gram-negative sepsis. Crit Care Med 20:730–735
Greenman RL, Schein RM, Martin MA, Wenzel RP, MacIntyre NR, Emmanuel G, Chmel H, Kohler RB, McCarthy M, Plouffe J, Russell JA, the Xoma Sepsis Study Group (1991) A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. JAMA 266:1097–1125
Iwata M, Shimozato T, Tokiwa H, Tsubura E (1987) Antipyretic activity of a human immunoglobulin preparation for intravenous use in an experimental model of fever in rabbits. Infect Immun 55:547–554
Jackson SK, Parton J, Barnes A, Poynton CH, Fegan C (1993) Effect of IgM-enriched intravenous immunoglobulin (Pentaglobin) on endotoxemia and anti-endotoxin anti-bodies in bone marrow transplantation. Eur J Clin Invest 23:540–545
Jesdinsky HJ, Tempel G, Castrup HJ, Seifert J (1987) Cooperative group of additional immunoglobulin therapy in severe bacterial infections: results of a multicenter randomized controlled trial in cases of diffuse fibrinopurulent peritonitis. Klin Wochenschr 67:1132–1138
McCabe WR, DeMaria A J, Berberich H, Johns MA (1988) Immunisation with rough mutants of Salmonella minnesota: protective activity of IgM and IgG antibody to the R595(Re chemotype) mutant. J Infect Dis 158:291–300
McCloskey RV, Straube RC, Sanders C, Smith SM, Smith CR the CHESS Trial Study Group (1994) Treatment of septic shock with human nonoclonal antibody HA-1A. Ann Intern Med 121:1–5
Mileski WJ (1991) Sepsis — what it is and how to recognize it. Surg Clin North Am 71:749–764
Nitsche D, Kriewitz M, Rossberg A, Hamelmann H (1987) The quantitative determination of endotoxin in plasma samples of septic patients with the peritonitis using the chromogenic substrate and its correlation with the clinical course of peritonitis. In: Watson SW (ed) Detection of bacterial endotoxin with Limulus amoebocyte lysate test. AR Liss, New York, pp 417–429
Nitsche D, Schulze C, Oesser S, Dalhoff A, Sack M (1996) Impact of different of classes of antimicrobial agents on plasma endotoxin activity. Arch Surg 131:192–199
Opal SM, Yu RL Jr (1998) Anitendotoxin strategies for the prevention and treatment of septic shock. New approaches and future directions. Drugs 55(4):497–508
Pollack M, Huang AI, Prescott RK, Young LS, Hunter KW, Cruess DF, Tsai CM (1983) Enhanced survival in Pseudomonas aeruginosa septicemia associated with high levels of circulating antibody to Escherichia coli endotoxin core. J Clin Invest 72:1874–1881
Poynton CH, Jackson S, Fegan C, Barnes RA, Whittaker JA (1992) Use of IgM enriched intravenous immunoglobulin (Pentaglobin) in bone marrow transplantation. Bone Marrow Transplant 9:451–457
Reuben AG, Musher DM, Hamil RJ, Broucke I (1989) Polymicrobial bacteremia: clinical and microbiologic patterns. Rev Infect Dis 11:161–183
Rietschel ET, Schade U, Jensen M, Wollenweber HW, Lüderitz O, Greisman SG (1982) Bacterial endotoxins: chemical structure, biological activity and the role in septicaemia. Scand J Infect Dis [Suppl] 31:8–21
Rintala E, Pulkki K, Mertsola J, Nevalainen T, Nikoskelainen J (1995) Endotoxin, interleukin-6 and pospholipase-A2 as markers of sepsis in patients with hematological malignancies. Scand J Infect Dis 27:39–43
Saladino R, Baldwin G, Alpert G, Parsonnet J, Gillis Z, Thompson C, Siber G, Fleisher G (1992) Effect of a human immunoglobulin preparation for intravenous use in a rabbit model of meningococcal endotoxin-induced shock. Crit Care Med 20:816–822
Schedel I, Dreikhausen U, Nentwig B, Höckenschnieder M, Rauthmann D, Balikcioglu S, Coldewey R, Deicher H (1991) Treatment of gram-negative septic shock with an immunoglobulin preparation: a prospective, randomized clinical trial. Crit Care Med 19:1104–1113
Shimozato T, Iwata M, Tamura N (1990) Suppression of tumor necrosis factor-alpha production by human immunoglobulin preparation for intravenous use. Infect Immun 58:1384–1390
Teng NH, Kaplan HS, Hebert JM, Moore C, Douglas H, Wunderlich A, Braude AL (1985) Protection against gram-negative bacteremia and endotoxemia with human monoclonal IgM antibodies. Proc Natl Acad Sci USA 82:1790–1794
Trautmann M, Held TK, Susa M, Karajan MA, Wulf A, Cross AS, Marre R (1998) Bacterial lipopolysaccharide (LPS)-specific antibodies in commercial human immunoglobulin preparations: superior antibody content of an IgM-enriched product. Clin Exp Immunol 111:81–90
Ulmer AJ, Heine H, Feist W, Kusumoto S, Kusama T, Brade H, Schade U, Rietschel ET, Flad HD (1992) Biological activity of synthetic phosphonooxyethyl analogs of lipid A and lipid A partical structures. Infect Immun 60:3309–3314
Werdan K, Pilz G (1996) Supplemental immune globulins in sepsis: a critical appraisal. Clin Exp Immunol 104[Suppl.1]: 83–90
Ziegler EJ, McCutchan JA, Fierer J, Glauser MP, Sadoff JC, Douglas H, Braude AL (1982) Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli. N Engl J Med 307:1225–1230
Ziegler EJ, Fisher CJ, Sprung CL, Straube RC, Sadoff JC, Foulke GE, Wortel CH, Fink MP, Dellinger RP, Teng NH, Allen IE, Berger HJ, Knatterud GL, LoBuglio AF, Smith CR, et al (1991) Treatment of gram-negative bacteremia and septic shock with HA-1 A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. N Engl J Med 324: 429–436
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Oesser, S., Schulze, C. & Seifert, J. Protective capacity of a IgM/IgA-enriched polyclonal immunoglobulin-G preparation in endotoxemia. Res. Exp. Med. 198, 325–339 (1998). https://doi.org/10.1007/s004330050115
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s004330050115